Robert M. MacRae
YOU?
Author Swipe
View article: Effectiveness of palliative hemostatic radiotherapy for hemoptysis: a prospective single-arm observation study
Effectiveness of palliative hemostatic radiotherapy for hemoptysis: a prospective single-arm observation study Open
Hemostatic RT remains an effective modality for controlling hemoptysis. The short interval high mortality rate post-RT challenges whether fractionated palliative RT should be used for this patient population. Conducting a large clinical tr…
View article: The introduction of a dedicated cardiology clinic including a clinical scientist led pathway for women with turner's syndrome
The introduction of a dedicated cardiology clinic including a clinical scientist led pathway for women with turner's syndrome Open
Background There are more than 15,000 women living with Turner’s Syndrome (TS) in the UK, over 700 of whom are cared for within our linked Endocrinology services. Mortality is predominantly related to cardiovascular disease therefore close…
View article: Long-Term Prospective Outcomes of Intensity Modulated Radiotherapy for Locally Advanced Lung Cancer
Long-Term Prospective Outcomes of Intensity Modulated Radiotherapy for Locally Advanced Lung Cancer Open
Importance The optimal radiotherapy technique for unresectable locally advanced non–small cell lung cancer (NSCLC) is controversial, so evaluating long-term prospective outcomes of intensity-modulated radiotherapy (IMRT) is important. Obje…
View article: Real-World Evaluation of Primary Versus Secondary Prevention of Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer
Real-World Evaluation of Primary Versus Secondary Prevention of Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer Open
Introduction Anti-osteoclast treatment with denosumab or zoledronate is known to effectively reduce the need for radiotherapy to bone and other skeletal-related events (SREs) in patients with metastatic castration-resistant prostate cancer…
View article: Variation in Access to Palliative Radiotherapy in Prostate Cancer: A Population-Based Study in Canada
Variation in Access to Palliative Radiotherapy in Prostate Cancer: A Population-Based Study in Canada Open
We found the utilization of palliative radiotherapy for prostate cancer patients in Ontario varies depending on age, stage at diagnosis, number of comorbidities, registration at regional cancer centers, and involvement of oncologists. Ther…
View article: Supplementary Data Table 4 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC
Supplementary Data Table 4 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC Open
Pretreatment Characteristics by KRAS Analysis Inclusion Status
View article: TABLE 4 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC
TABLE 4 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC Open
Worst treatment-related toxicity logistic regression model of KRAS and cetuximab interaction
View article: TABLE 3 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC
TABLE 3 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC Open
LF within non-variant patients by as-treated cetuximab
View article: Supplementary Data Table 7 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC
Supplementary Data Table 7 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC Open
Pretreatment Characteristics by KRAS-variant or non-variant status
View article: TABLE 1 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC
TABLE 1 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC Open
OS within KRAS-variant patients by as-treated cetuximab
View article: Supplementary Data Table 10 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC
Supplementary Data Table 10 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC Open
Overall Survival within non-variant Patients Cetuximab Assignment
View article: Supplementary Data Table 5 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC
Supplementary Data Table 5 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC Open
Best Observed Response by KRAS Analysis Inclusion Status
View article: Supplementary Data Table 3 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC
Supplementary Data Table 3 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC Open
KRAS Analysis Inclusion Status
View article: Supplementary Data Table 14 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC
Supplementary Data Table 14 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC Open
Worst Treatment-Related Toxicity within Non-variant Patients By Cetuximab Assignment
View article: FIGURE 1 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC
FIGURE 1 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC Open
OS by KRAS and treatment arm. A, OS in non-variant patients by radiation level; B, OS in non-variant patients by cetuximab; C, OS in KRAS-variant patients by radiation level; D, OS within KRAS-variant patients by cetuximab. Radiation level…
View article: Supplementary Data Table 2 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC
Supplementary Data Table 2 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC Open
Representativeness of Study Participants
View article: Data from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC
Data from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC Open
Purpose:RTOG 0617 was a phase III randomized trial for patients with unresectable stage IIIA/IIIB non–small cell lung cancer comparing standard-dose (60 Gy) versus high-dose (74 Gy) radiotherapy and chemotherapy, plus or minus cetuximab. A…
View article: Supplementary Data Table 1 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC
Supplementary Data Table 1 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC Open
Endpoints evaluated in RTOG 0617
View article: TABLE 2 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC
TABLE 2 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC Open
OS models within KRAS-variant: time-varying cetuximab effect
View article: Supplementary Data Table 13 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC
Supplementary Data Table 13 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC Open
Worst Treatment-Related Toxicity Logistic Regression Model of KRAS and As-Treated RT Interaction
View article: Supplementary Data Table 8 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC
Supplementary Data Table 8 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC Open
Overall Survival
View article: TABLE 2 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC
TABLE 2 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC Open
OS models within KRAS-variant: time-varying cetuximab effect
View article: Supplementary Data Table 10 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC
Supplementary Data Table 10 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC Open
Overall Survival within non-variant Patients Cetuximab Assignment
View article: Supplementary Data Table 8 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC
Supplementary Data Table 8 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC Open
Overall Survival
View article: Supplementary Data Table 11 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC
Supplementary Data Table 11 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC Open
Local Failure within KRAS Variant Patients by As-Treated Cetuximab
View article: Supplementary Data Table 14 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC
Supplementary Data Table 14 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC Open
Worst Treatment-Related Toxicity within Non-variant Patients By Cetuximab Assignment
View article: Supplementary Data Table 4 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC
Supplementary Data Table 4 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC Open
Pretreatment Characteristics by KRAS Analysis Inclusion Status
View article: Supplementary Data Table 1 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC
Supplementary Data Table 1 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC Open
Endpoints evaluated in RTOG 0617
View article: Supplementary Data Table 15 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC
Supplementary Data Table 15 from The Inherited <i>KRAS</i>-variant as a Biomarker of Cetuximab Response in NSCLC Open
Worst Treatment-Related Toxicity within KRAS-Variant Patients By Cetuximab